Biofrontera Inc

biofrontera-us.com

What Do They Do?

Sells Ameluz, a prescription drug, and RhodoLED lamps for light-based treatment of precancerous skin lesions to dermatology practices and other healthcare providers.

How Do They Make Money?

Physicians, hospitals and other qualified healthcare providers buy Ameluz when it is delivered; lamp sales are completed after installation, while rentals and evaluation periods bring monthly fees.

FY2025 revenue

Who Are Their Customers?

Dermatology offices and groups, hospitals, and other qualified healthcare providers buy directly through the company's U.S. sales organization.

Do Revenues Turn Into Profits?

No. It lost $10.5M in FY2025.

Operating income, FY2025

−27% of revenue

▼ −34% (Loss) vs FY2024 (−$17.2M, −46%)

Net income, FY2025

−25% of revenue

▼ −41% (Loss) vs FY2024 (−$17.8M, −48%)

Free cash flow, FY2025

−32% of revenue

▲ +30% (Loss) vs FY2024 (−$10.3M, −28%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +33%; vs $9M in Q2 FY2025
Net income: ▼ −89% (Loss); vs −$5.3M in Q2 FY2025

Sep 14, 2026 FDA approves Ameluz for superficial basal cell carcinoma The approval allows Ameluz with BF-RhodoLED lamps to treat superficial basal cell carcinoma in adults.

Portfolio scope The portfolio has narrowed from licensed photodynamic therapy products plus a topical antibiotic for impetigo to products centered on Ameluz and RhodoLED for photodynamic therapy.

Research and product rights The company described itself as a sales organization selling licensed products, with licensors handling research; it now develops products, runs Ameluz trials, and holds U.S. rights to Ameluz and RhodoLED.

Comments